AR114140A1 - Composiciones orales de rifamicina sv - Google Patents
Composiciones orales de rifamicina svInfo
- Publication number
- AR114140A1 AR114140A1 ARP180103244A ARP180103244A AR114140A1 AR 114140 A1 AR114140 A1 AR 114140A1 AR P180103244 A ARP180103244 A AR P180103244A AR P180103244 A ARP180103244 A AR P180103244A AR 114140 A1 AR114140 A1 AR 114140A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- pharmaceutical compositions
- oral pharmaceutical
- rifamycin
- prevention
- Prior art date
Links
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical group OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 title abstract 3
- 229940109171 rifamycin sv Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 3
- HJYYPODYNSCCOU-ZDHWWVNNSA-N Rifamycin SV Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(O)c4c3C2=O HJYYPODYNSCCOU-ZDHWWVNNSA-N 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 210000000813 small intestine Anatomy 0.000 abstract 2
- 206010008631 Cholera Diseases 0.000 abstract 1
- 208000012868 Overgrowth Diseases 0.000 abstract 1
- 206010062070 Peritonitis bacterial Diseases 0.000 abstract 1
- 208000002389 Pouchitis Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 210000001198 duodenum Anatomy 0.000 abstract 1
- 208000007386 hepatic encephalopathy Diseases 0.000 abstract 1
- 208000008384 ileus Diseases 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 210000001630 jejunum Anatomy 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584226P | 2017-11-10 | 2017-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114140A1 true AR114140A1 (es) | 2020-07-29 |
Family
ID=64426987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103244A AR114140A1 (es) | 2017-11-10 | 2018-11-07 | Composiciones orales de rifamicina sv |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11564883B2 (https=) |
| EP (3) | EP4438039A3 (https=) |
| JP (2) | JP2021502382A (https=) |
| KR (1) | KR102747348B1 (https=) |
| CN (1) | CN111328279B (https=) |
| AR (1) | AR114140A1 (https=) |
| AU (1) | AU2018364617B2 (https=) |
| BR (1) | BR112020009171A2 (https=) |
| CA (1) | CA3078900A1 (https=) |
| DK (1) | DK3706724T3 (https=) |
| ES (1) | ES2989706T3 (https=) |
| FI (1) | FI3706724T3 (https=) |
| IL (1) | IL274414B2 (https=) |
| MX (1) | MX2020004706A (https=) |
| PL (1) | PL3706724T3 (https=) |
| WO (1) | WO2019092614A1 (https=) |
| ZA (1) | ZA202002726B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022102198A (ja) * | 2020-12-25 | 2022-07-07 | ライオン株式会社 | 内服固形剤 |
| US20220280478A1 (en) * | 2021-03-05 | 2022-09-08 | Bausch Health Ireland, Limited | Methods of using rifamycin sv for the treatment of sickle cell disease |
| EP4412588A1 (en) * | 2021-10-05 | 2024-08-14 | Cosmo Technologies Ltd | An in-situ gelling enema of rifamycin for treating pouchitis and distal ulcerative colitis |
| WO2025064599A1 (en) * | 2023-09-19 | 2025-03-27 | The United States Government As Represented By The Department Of Veterans Affairs | Rifamycin composition for treating sarcopenia |
| WO2025157240A1 (zh) * | 2024-01-26 | 2025-07-31 | 丹诺医药（苏州）股份有限公司 | 化合物用于制备治疗细菌代谢相关疾病的药物的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| CA2377301C (en) | 1999-06-14 | 2009-05-12 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| WO2005030173A1 (en) | 2003-09-25 | 2005-04-07 | Ranbaxy Laboratories Limited | Colon-specific drug delivery using interpolymer complexations |
| ITMI20041295A1 (it) | 2004-06-25 | 2004-09-25 | Cosmo Spa | Composizioni farmaceutiche antimicrobiche orali |
| KR20080081351A (ko) | 2006-01-04 | 2008-09-09 | 도꾜 메디칼 앤드 덴탈 유니버시티 | 간장 질환 치료제 및 간기능 개선제 |
| BRPI0908026B8 (pt) | 2008-02-26 | 2021-05-25 | Salix Pharmaceuticals Ltd | uso de rifaximina no tratamento de doenças do intestino |
| HRP20200284T1 (hr) | 2008-10-02 | 2020-07-10 | Salix Pharmaceuticals, Ltd. | Postupci liječenja hepatičke encefalopatije |
| US7928115B2 (en) * | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
| US8741048B2 (en) | 2011-08-30 | 2014-06-03 | Brother Kogyo Kabushiki Kaisha | Water-based ink for ink-jet recording and ink cartridge |
| IN2014DN06662A (https=) | 2012-02-13 | 2015-05-22 | Cosmo Technologies Ltd | |
| WO2016003536A1 (en) | 2014-06-30 | 2016-01-07 | Salix Pharmaceuticals, Inc. | Methods for retreating irritable bowel syndrome (ibs) |
| WO2017053885A1 (en) * | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
-
2018
- 2018-11-07 EP EP24193102.1A patent/EP4438039A3/en active Pending
- 2018-11-07 EP EP24192746.6A patent/EP4431094A3/en active Pending
- 2018-11-07 JP JP2020526001A patent/JP2021502382A/ja active Pending
- 2018-11-07 PL PL18807426.4T patent/PL3706724T3/pl unknown
- 2018-11-07 CA CA3078900A patent/CA3078900A1/en active Pending
- 2018-11-07 AU AU2018364617A patent/AU2018364617B2/en active Active
- 2018-11-07 WO PCT/IB2018/058748 patent/WO2019092614A1/en not_active Ceased
- 2018-11-07 DK DK18807426.4T patent/DK3706724T3/da active
- 2018-11-07 US US16/762,760 patent/US11564883B2/en active Active
- 2018-11-07 CN CN201880072798.7A patent/CN111328279B/zh active Active
- 2018-11-07 ES ES18807426T patent/ES2989706T3/es active Active
- 2018-11-07 BR BR112020009171-5A patent/BR112020009171A2/pt unknown
- 2018-11-07 EP EP18807426.4A patent/EP3706724B1/en active Active
- 2018-11-07 IL IL274414A patent/IL274414B2/en unknown
- 2018-11-07 KR KR1020207014333A patent/KR102747348B1/ko active Active
- 2018-11-07 MX MX2020004706A patent/MX2020004706A/es unknown
- 2018-11-07 FI FIEP18807426.4T patent/FI3706724T3/fi active
- 2018-11-07 AR ARP180103244A patent/AR114140A1/es unknown
-
2020
- 2020-05-13 ZA ZA2020/02726A patent/ZA202002726B/en unknown
-
2022
- 2022-12-27 US US18/146,510 patent/US12036316B2/en active Active
-
2023
- 2023-06-21 JP JP2023101775A patent/JP7651620B2/ja active Active
-
2024
- 2024-05-30 US US18/678,539 patent/US20240398699A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114140A1 (es) | Composiciones orales de rifamicina sv | |
| CY1124052T1 (el) | Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη | |
| PE20210401A1 (es) | Composiciones farmaceuticas que comprenden meloxicam | |
| MX2012005365A (es) | Formulaciones de tableta de liberacion inmediata. | |
| CR8569A (es) | Inhibidores de integrasa de vih | |
| MX2020008017A (es) | Formulaciones de vidrio y usos de las mismas. | |
| PH12019502782A1 (en) | Fixed dose formulations | |
| MX394857B (es) | Composicion farmaceutica para administracion oral que comprende enzalutamida. | |
| EA201791067A1 (ru) | Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса | |
| MX2019008302A (es) | Inhibidores biciclicos de histona desacetilasa. | |
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| PH12021550237A1 (en) | Bioavailable oral dosage forms. | |
| MY204588A (en) | Delayed release deferiprone tablets and methods of using the same | |
| MX385518B (es) | FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE. | |
| CO6731095A2 (es) | Composición farmacéutica de administración oral para el tratamiento del síndrome de intestino irritable digestivas a base de un modificador de la motilidad intestinal, un agente que previene la retención de gases y enzimas digestivas y proceso para su preparación | |
| DOP2013000109A (es) | COMPOSICIÓN FARMACÉUTICA ADAPTADA PARA ADMINISTRARSE ORALMENTE Y PROCESO PARA SU PREPARACIÓN, PARA PREVENCIÓN Y TRATAMIENTO DEL SÍNDROME DE INTESTINO IRRITABLE, A BASE DE UN MODIFICADOR DE LA MOTILIDAD INTESTINAL Y a-D- GALACTOSIDASA. | |
| TR201721700A2 (tr) | Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari | |
| EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
| CY1120847T1 (el) | Σχημα αγωγης ενωσης τιακουμικινης | |
| CL2020001180A1 (es) | Régimen de dosificación de edasalonexent para el tratamiento de distrofia muscular. | |
| PH12016502591A1 (en) | Pharmaceutical for treating dizziness having different causes | |
| MX391381B (es) | EL USO DE 3ß-ARAQUIDILAMINO-7A,12A-DIHIDROXI-5ß-COLAN-24-OICO (ARAMCHOL) PARA INHIBIR LA FIBROSIS HEPÁTICA EN UN SUJETO QUE PADECE ENFERMEDAD DE HÍGADO GRASO. | |
| AR100262A1 (es) | Tratamiento de la enfermedad de crohn con 6-mercaptopurina de liberación demorada | |
| Henriksen | Parkinsonism: case report | |
| Abe | Case Presentations: Intraluminal Growth |